REGN Regeneron Pharmaceuticals
- 973.800
- +5.800+0.60%
- 973.000
- -0.800-0.08%
Regeneron Pharmaceuticals News
US stocks closed | The Federal Reserve hawked to suppress US stocks, the NASDAQ fell, the Dow still rose eight times in a row, and the Krypton debut soared more than 34%
S&P has declined in the short term several times. The Dow rose more than 2% this week, the biggest weekly gain in nearly five months. Tesla closed down 2% and fell four times in a row. Nvidia rebounded more than 1% after three consecutive declines, and TSMC's US stock, which saw a sharp increase in sales in April, rose 4.5%.
Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) Large Institutional Owners Must Be Happy as Stock Continues to Impress, up 3.2% Over the Past Week
There May Be Reason For Hope In Regeneron Pharmaceuticals' (NASDAQ:REGN) Disappointing Earnings
The market was pleased with the recent earnings report from Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN), despite the profit numbers being soft. Our analysis suggests that investors may have noticed
Regeneron Gene Therapy Improves Hearing in Child Deafness
Regeneron Announces Prelim. Data In An ASGCT Presentation Showing DB-OTO Improved Hearing To Normal Levels In One Child Within 24 Weeks, Initial Hearing Improvements Observed In A Second Child At 6-Week Assessment
Regeneron Announces Prelim. Data In An ASGCT Presentation Showing DB-OTO Improved Hearing To Normal Levels In One Child Within 24 Weeks, Initial Hearing Improvements Observed In A Second Child At 6-We
Latest DB-OTO Results Show Dramatically Improved Hearing to Normal Levels in a Child With Profound Genetic Deafness Within 24 Weeks and Initial Hearing Improvements in a Second Child at 6 Weeks
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the investigational gene therapy DB-OTO improved hearing to normal levels in one child (dosed at 11 months of age) within 24 weeks, and initial hearing improvements were observed in a second child (dosed at 4 years of age) at a 6-week assessment.
UBS Raises Regeneron Pharmaceuticals Price Target to $1,124 From $1,099, Maintains Buy Rating
Regeneron Pharmaceuticals (REGN) has an average rating of outperform and price targets ranging from $720 to $1,185, according to analysts polled by Capital IQ. Price: 961.12, Change: +2.48, Percent Ch
Apple's $110B Buyback Is Larger Than the Market Caps of 418 S&P 500 Stocks
Regeneron Announces Investor Conference Presentations
TARRYTOWN, N.Y., May 06, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management participation as follows:RBC Capital Markets Global Healthcare Conference at
23 Most Profitable Stocks of the Last 12 Months
In this article, we discuss the 23 most profitable stocks of the last 12 months.
Regeneron Pharmaceuticals(REGN.US) Officer Sells US$222.35K in Common Stock
$Regeneron Pharmaceuticals(REGN.US)$ Officer McCourt Marion sold 250 shares of common stock on May 1, 2024 at an average price of $889.41 for a total value of $222.35K.Source: Announcement What is sta
Regeneron Pharmaceuticals(REGN.US) Director Sells US$89,960.51 in Common Stock
$Regeneron Pharmaceuticals(REGN.US)$ Director RYAN ARTHUR F sold 100 shares of common stock on May 1, 2024 at an average price of $899.61 for a total value of $89,960.51.Source: Announcement What is s
Catalyst Watch: Disney Earnings, Apple iPad Event and Fed Speakers Back on the Circuit
Cantor Fitzgerald: Regeneron Pharmaceuticals (REGN.US) rating was reaffirmed, adjusted from neutral to neutral, with a target price of $925.00.
Cantor Fitzgerald: Regeneron Pharmaceuticals (REGN.US) rating was reaffirmed, adjusted from neutral to neutral, with a target price of $925.00.
Cantor Fitzgerald Reiterates Neutral on Regeneron Pharmaceuticals, Maintains $925 Price Target
Cantor Fitzgerald analyst Olivia Brayer reiterates Regeneron Pharmaceuticals with a Neutral and maintains $925 price target.
Regeneron Pharmaceuticals Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/03/2024 -1.51% Cantor Fitzgerald → $925 Reiterates Neutral → Neutral 04/24/2024 9.67% TD Cowen $1020 →
Goldman Sachs Adjusts Price Target on Regeneron Pharmaceuticals to $1,180 From $1,126
Regeneron Pharmaceuticals (REGN) has an average outperform rating and price target range of $720 to $1,185, according to analysts polled by Capital IQ. Price: 942.39, Change: +4.78, Percent Change: +0
Regeneron Pharmaceuticals First Quarter 2024 Earnings: Misses Expectations
Regeneron Pharmaceuticals Inc (REGN) Q1 2024 Earnings Call Transcript Highlights: Key Financial ...
Decoding Regeneron Pharmaceuticals Inc (REGN): A Strategic SWOT Insight
Analysis
Price Target
No Data
